Studies have implicated intake of monosodium glutamate (MSG) in fibroid development, but reports on the correlation between dyslipidemia and fibroid induction with an intake of MSG are inconsistent. This study investigates the risk of dyslipidemia in MSG intake and the therapeutic effect of administration of Phyllanthus amarus. Forty adult female Wistar rats randomize to 5 groups of 8 rats each were used. MSG was administered continuously to groups 2-5 at 200 mg/Kg body weight for 28 days. After 28 days, blood was withdrawn from rats in groups1, 2 and 3after anaesthetizing with diethyl ether. They were then sacrificed and the uterus, kidney and liver excised. MSG administrations were later discontinued in the remaining groups of rats, and P. amarus leaves extract was administered daily to group 4. Treatments were later continued for the next 28 days after which the rats were sacrificed. Total cholesterol (TC), Low-density lipoprotein (LDL-c), High-density lipoprotein (HDL-c), triglyceride, artherogenic (AI) and coronary risk index (CRI), glucose and total protein were then determined in the serum. The organs were also weighed, and the uterus was used for histopathology studies. Results indicate that serum cholesterol, LDL-c, triglycerides, API, CRI and glucose were raised with MSG administration whereas; HDL-c was reduced. Co-administration of P. amarus with MSG prevented these alterations. Withdrawal of MSG without treatment and administration of P. amarus after MSG administration also reduced the cholesterol, triglyceride, LDL, AI and CRI. Although the final body weights and uterine weight ratio were increased with MSG administration and co-administration of P. amarus with MSG prevented these alterations, no observable difference was observed in the histology of the uterine tissues. The study suggests that MSG administration is positively correlated with dyslipidemia and uterine toxicity. Results also show that co-administration of P. amarus with MSG may offer protection against these metabolic changes